Vertex has acquired the full assets to a promising protease-based drug platform from Catalyst, broadening its R&D base once again.

Dexcom may be planning to purchase Insulet to enter the insulin pump market and transform itself into a diabetes tech giant.

Xevudy, which was part of the deal, has already seen restrictions on its use due to diminished efficacy against Omicron. Plus, Ocugen is back in the game as the FDA has released the clinical hold on its Phase II/III vaccine trial, while Pfizer/BioNTech release new booster shot data for Comirnaty in children aged 6 months-5 years.

Microbot Medical CEO Harel Gadot said a recent regulatory filing marks an important milestone in his company' efforts to bring the world’s first fully disposable endovascular robot to market.